Zealand Pharma A/S (ZLDPF)
USD 64.82
(1.61%)
USD 64.82
(1.61%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -572.23 Million DKK | 29.92% |
| 2022 | -816.59 Million DKK | 22.24% |
| 2021 | -1.05 Billion DKK | -26.72% |
| 2020 | -828.75 Million DKK | -40.96% |
| 2019 | -587.94 Million DKK | -190.12% |
| 2018 | 652.39 Million DKK | 364.79% |
| 2017 | -246.38 Million DKK | -113.05% |
| 2016 | -115.64 Million DKK | -42.2% |
| 2015 | -81.32 Million DKK | -10.59% |
| 2014 | -73.53 Million DKK | 60.38% |
| 2013 | -185.61 Million DKK | -672.95% |
| 2012 | 32.39 Million DKK | 269.66% |
| 2011 | 8.76 Million DKK | 108.06% |
| 2010 | -108.69 Million DKK | -36.0% |
| 2009 | -79.92 Million DKK | -78.85% |
| 2008 | -44.68 Million DKK | 28.53% |
| 2007 | -62.52 Million DKK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -267.67 Million DKK | -4.63% |
| 2024 Q1 | -255.84 Million DKK | -0.93% |
| 2023 Q1 | -168.67 Million DKK | 29.25% |
| 2023 FY | -572.23 Million DKK | 29.92% |
| 2023 Q4 | -253.47 Million DKK | -659.82% |
| 2023 Q3 | 45.27 Million DKK | 123.18% |
| 2023 Q2 | -195.36 Million DKK | -15.82% |
| 2022 Q4 | -238.4 Million DKK | -47.1% |
| 2022 FY | -816.59 Million DKK | 22.24% |
| 2022 Q3 | -162.07 Million DKK | 31.67% |
| 2022 Q2 | -237.2 Million DKK | 21.46% |
| 2022 Q1 | -301.99 Million DKK | -4.23% |
| 2021 Q4 | -289.74 Million DKK | -36.8% |
| 2021 Q2 | -289.91 Million DKK | -11.12% |
| 2021 FY | -1.05 Billion DKK | -26.72% |
| 2021 Q1 | -260.9 Million DKK | 23.99% |
| 2021 Q3 | -211.8 Million DKK | 26.94% |
| 2020 Q3 | -218.2 Million DKK | -306.27% |
| 2020 Q2 | -53.71 Million DKK | 69.69% |
| 2020 FY | -828.75 Million DKK | -40.96% |
| 2020 Q1 | -177.2 Million DKK | 4.63% |
| 2020 Q4 | -343.24 Million DKK | -57.3% |
| 2019 FY | -587.94 Million DKK | -190.12% |
| 2019 Q1 | -135.78 Million DKK | 1.39% |
| 2019 Q2 | -136.28 Million DKK | -0.37% |
| 2019 Q3 | -130.06 Million DKK | 4.57% |
| 2019 Q4 | -185.8 Million DKK | -42.86% |
| 2018 Q4 | -137.69 Million DKK | -113.69% |
| 2018 Q2 | -131.93 Million DKK | -59.89% |
| 2018 Q1 | -82.51 Million DKK | 25.04% |
| 2018 FY | 652.39 Million DKK | 364.79% |
| 2018 Q3 | 1 Billion DKK | 862.13% |
| 2017 Q2 | -94.77 Million DKK | -2752.86% |
| 2017 FY | -246.38 Million DKK | -113.05% |
| 2017 Q4 | -110.07 Million DKK | -188.04% |
| 2017 Q3 | -38.21 Million DKK | 59.68% |
| 2017 Q1 | -3.32 Million DKK | -105.72% |
| 2016 Q1 | -64.67 Million DKK | -183.98% |
| 2016 Q4 | 58.04 Million DKK | 373.96% |
| 2016 Q3 | -21.18 Million DKK | 75.93% |
| 2016 Q2 | -88.01 Million DKK | -36.08% |
| 2016 FY | -115.64 Million DKK | -42.2% |
| 2015 Q2 | -64.56 Million DKK | -30.41% |
| 2015 Q4 | 77 Million DKK | 274.01% |
| 2015 FY | -81.32 Million DKK | -10.59% |
| 2015 Q1 | -49.51 Million DKK | 27.15% |
| 2015 Q3 | -44.25 Million DKK | 31.46% |
| 2014 Q3 | 13.93 Million DKK | 128.95% |
| 2014 Q4 | -67.96 Million DKK | -587.89% |
| 2014 FY | -73.53 Million DKK | 60.38% |
| 2014 Q1 | 28.6 Million DKK | 163.02% |
| 2014 Q2 | -48.11 Million DKK | -268.18% |
| 2013 FY | -185.61 Million DKK | -672.95% |
| 2013 Q4 | -45.39 Million DKK | -29.71% |
| 2013 Q3 | -34.99 Million DKK | 26.03% |
| 2013 Q2 | -47.31 Million DKK | 18.31% |
| 2013 Q1 | -57.91 Million DKK | -4.62% |
| 2012 Q2 | 22.16 Million DKK | -66.23% |
| 2012 Q1 | 65.63 Million DKK | 421.41% |
| 2012 FY | 32.39 Million DKK | 269.66% |
| 2012 Q4 | -55.36 Million DKK | -141848.72% |
| 2012 Q3 | -39 Thousand DKK | -100.18% |
| 2011 Q2 | 91.71 Million DKK | 311.74% |
| 2011 Q4 | -20.42 Million DKK | -6.26% |
| 2011 Q1 | -43.31 Million DKK | 31.35% |
| 2011 FY | 8.76 Million DKK | 108.06% |
| 2011 Q3 | -19.21 Million DKK | -120.95% |
| 2010 Q1 | -25.67 Million DKK | 0.0% |
| 2010 FY | -108.69 Million DKK | -36.0% |
| 2010 Q2 | 31.44 Million DKK | 222.49% |
| 2010 Q3 | -51.37 Million DKK | -263.38% |
| 2010 Q4 | -63.09 Million DKK | -22.8% |
| 2009 FY | -79.92 Million DKK | -78.85% |
| 2008 FY | -44.68 Million DKK | 28.53% |
| 2007 FY | -62.52 Million DKK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Qrons Inc. | -643.67 Thousand USD | -88801.421% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 799.114% |
| Nascent Biotech, Inc. | -2.22 Million USD | -25562.289% |
| Adynxx, Inc. | - USD | Infinity% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -3505.844% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -45460.35% |
| BioStem Technologies, Inc. | -7.77 Million USD | -7256.219% |
| CSL Limited | 3.7 Billion USD | 115.458% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -11243.838% |
| Evofem Biosciences, Inc. | -17.84 Million USD | -3106.354% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | -930.911% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -83201.259% |
| Skye Bioscience, Inc. | -13.67 Million USD | -4085.535% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -137629.705% |
| Rebus Holdings, Inc. | -664 Thousand USD | -86080.422% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -42750.436% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -146789.648% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | -697.144% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 11743.133% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -218540.105% |
| SQZ Biotechnologies Company | -75.82 Million USD | -654.682% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -19974.955% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -37153.89% |
| Mesoblast Limited | -84.14 Million USD | -580.046% |
| Marizyme, Inc. | -34.08 Million USD | -1578.781% |
| Genus plc | 6.4 Million USD | 9041.219% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 5973.651% |
| Pharming Group N.V. | -4.87 Million USD | -11627.284% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -28706.647% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -61339.799% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | -6753.15% |
| ContraFect Corporation | -56.88 Million USD | -905.885% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -12463.61% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -40716.097% |
| IMV Inc. | -38.67 Million USD | -1379.74% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -20702.308% |
| MultiCell Technologies, Inc. | -722.81 USD | -79168422.848% |
| ONE Bio Corp. | 13.68 Million USD | 4282.553% |
| Accustem Sciences Inc. | -3.74 Million USD | -15174.266% |
| RVL Pharmaceuticals plc | -58.99 Million USD | -870.059% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -118360.57% |
| Q BioMed Inc. | -3.44 Million USD | -16507.713% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 16264.915% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -21678.619% |
| Biomind Labs Inc. | -1 Million USD | -56579.507% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | -940.956% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -19623.843% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -8507.652% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -30593.371% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -1910416.827% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -29509.595% |
| GB Sciences, Inc. | -1.42 Million USD | -40184.011% |
| Alpha Cognition Inc. | -9.7 Million USD | -5795.956% |
| HST Global, Inc. | -140.9 Thousand USD | -406010.413% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -50769.85% |
| Halberd Corporation | -75.05 Thousand USD | -762375.683% |
| Enzolytics Inc. | -2.14 Million USD | -26530.585% |
| Agentix Corp. | -1.37 Million USD | -41615.728% |
| Resverlogix Corp. | -12.74 Million USD | -4388.493% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -17961.506% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | -34.629% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -54712.069% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -19500.924% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -36132.386% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -16705.919% |
| AVAX Technologies, Inc. | 6.69 Million USD | 8649.952% |
| Zenith Capital Corp. | -8.94 Million USD | -6298.725% |
| Genscript Biotech Corporation | -415.79 Million USD | -37.626% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -3284659.773% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -23206.074% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -333547.913% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -28444.008% |
| Kadimastem Ltd | -3.04 Million USD | -18722.071% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -58051.136% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -315208.703% |
| LadRx Corporation | -3.82 Million USD | -14865.847% |
| Cell Source, Inc. | -4.32 Million USD | -13129.878% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -83201.259% |
| NovAccess Global Inc. | -2.46 Million USD | -23097.96% |
| Affymax, Inc. | -15.04 Million USD | -3703.257% |
| Itoco Inc. | -919.14 Thousand USD | -62157.98% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -13401.229% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -51038.338% |
| Mobile Lads Corp. | -554.55 Thousand USD | -103089.613% |
| CytoDyn Inc. | -18.05 Million USD | -3068.889% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -2273392.253% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -259915.994% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -101230.741% |
| SYBLEU INC | -149.18 Thousand USD | -383488.953% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -31405.351% |
| International Stem Cell Corporation | -663 Thousand USD | -86210.407% |
| Bioxytran, Inc. | -3.82 Million USD | -14879.476% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -1086978.267% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -2813262.832% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | -1477.891% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -35266.996% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -77667.162% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -18294.021% |
| Neutra Corp. | -229.48 Thousand USD | -249256.388% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | -3162.66% |
| PureTech Health plc | -146.19 Million USD | -291.41% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | -2562.672% |
| IXICO plc | -1.43 Million USD | -39721.712% |
| IntelGenx Technologies Corp. | -9.49 Million USD | -5929.27% |
| Gelesis Holdings, Inc. | -121.8 Million USD | -369.795% |
| CSL Limited | 3.81 Billion USD | 115.011% |
| Cellectis S.A. | -108.85 Million USD | -425.677% |